TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Noninvasive Neurostimulation of the Vagus Nerve for the Relief of Acute Bronchoconstriction Due to Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Is between the ages of 18 and 70 years.~2. Has been admitted to an emergency care facility with a working diagnosis of bronchoconstriction due to asthma.~3. Has an FEV1\<60% predicted.~4. Is available and willing to return for an office visit at 7 days and participate in a 30-day telephone call from time of discharge from the ED.~5. Is able to give written Informed Consent, or his/her legally authorized representative is available to give written Informed Consent.~Exclusion Criteria:~1. Has a history of lung cancer, chronic obstructive pulmonary disease (COPD), or other co-morbidity due to irreversible narrowing of the airways.~2. Is at risk of imminent respiratory collapse:~   * Lung Function: FEV1 \< 25% predicted~  * Signs and symptoms of extreme respiratory distress at rest, such as accessory muscle use, chest retraction~  * Consciousness State: Drowsy, confused~  * Rapid deterioration in respiratory status (sudden change in respiratory rate, decrease in oxygen saturation, change in consciousness, etc).~3. Has an abscess or other infection or lesion (including lymphadenopathy) at the therapy head placement site.~4. Has known or suspected atherosclerotic cardiovascular disease, carotid artery disease (e.g. bruits or history of TIA or CVA) or congestive heart failure (CHF).~5. Has suspected or confirmed sepsis.~6. Has a clinically significant irregular heart rate or rhythm.~7. Clinically significant changes in blood pressure or is receiving pressors to maintain blood pressure.~8. Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.~9. Has a history of carotid endarterectomy or vascular neck surgery on the right side.~10. Has been implanted with metal cervical spine hardware.~11. Has a condition that would interfere with VAS Dyspnea self-assessment.~12. Is pregnant.~13. Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.~14. Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g., homeless, developmentally disabled, prisoner).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- AlphaCore System (Type: EXPERIMENTAL): non-invasive vagus nerve stimulation (nVNS) using the AlphaCore System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cancer and Sexual Health : Early Information and Sexual Satisfaction of Couples in Oncology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients and partners declaring itself in couple or having a shared private life;~* Patients diagnosed by an initial cancer, the prognosis for survival of which at the time of the diagnosis is upper to one year;~* Patients and partners of more than 18 years old, mastering the French language, and in measure to give their informed consent~Exclusion Criteria:~* Patients having been diagnosed and/or treated for another cancer;~* Patients and partners having a psychiatric disorder (confusional syndrome, psychotic disorders, disrupted reality perception)~* Patients and partners protected by the law, according to articles L.1121-5 to L.1121-8 of the Public health code.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INFORMED (Type: EXPERIMENTAL): Interventional Group (I): Couples enrolled during the diagnosis will receive written information as usual about the disease and in addition they benefit special oral interviews and written information about experiences of their sexuality during the illness.The document used for the interventional group is Sexuality and Cancer and will be given to couples. (intervention: Oral information and interviews about sexuality and self experience during the disease). Qualitative analysis will be provided by a psychologist
- ORDINARY USE (Type: NO_INTERVENTION): Non-interventional Group (NI): Couples enrolled during the diagnosis will only receive written information about their experience of disease . The document used fot the non interventional group is Live during and after cancerand will be given to couples. Qualitative analysis will be provided by a psychologist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients with obstructive jaundice, and imaging (CT or MRI) suggestive of biliary stricture, without obvious pancreatic mass~2. All patients with obstructive jaundice, and index ERCP suggestive of biliary stricture, without obvious pancreatic mass~3. All patients with obstructive jaundice, and prior ERCP suggestive of biliary stricture~4. Expected patient survival of at least 90 days~5. High likelihood of patient follow-up~6. Patient is able to give a written informed consent~7. Patient is willing and able to comply with the study procedures~Exclusion Criteria:~1. Patients with imaging suggestive of pancreatic tumor~2. Children \< 18 years of age~3. Pregnant women~4. Patients with impaired decision-making~5. Healthy volunteers~6. Primary Sclerosing Cholangitis (PSC)~7. Patients with untreated coagulopathy at the time of procedure or ongoing need for anti-coagulation~8. Patients with any contraindication to endoscopic procedure~9. Participation in another investigational study that may directly or indirectly affect the results of this study within 30 days prior to the initial visit~10. Patients unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pediatric Biopsy Forceps directed biopsies (Type: EXPERIMENTAL): Biopsies of the stricture will be taken with Pediatric Biopsy Forceps after bile duct brushings have been obtained.
- Cholangioscopy-directed biopsies (Type: ACTIVE_COMPARATOR): Biopsies of the stricture will be taken under cholangioscopic guidance after bile duct brushings have been obtained.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Skin Imaging to Inform Laser Treatments

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Subjects must meet the following inclusion criteria:~* Ability to understand and carry out subject instructions or be represented by a legally authorized guardian or representative.~* Ages 4 and older. Patients younger than 4 may have difficulty cooperating with the OCT measurements because each measurement requires the patient to remain still for approximately 30 seconds.~* Seeks and is scheduled for laser treatment of a skin lesion. Exclusion Criteria~Any of the following will exclude participation in the study:~* Inability to understand and/or carry out subject instructions.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Prospective Study Group (Type: EXPERIMENTAL): For the experimental group, the laser surgeon will be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on the measurements.
- Prospective Control Group (Type: OTHER): For the control group, the laser surgeon will not be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on standard of care, intuition, and experience.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Infliximab Top-down in Pediatric Crohn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Children (age 3-17 years, both male and female) with new-onset, untreated CD with moderate-to-severe disease activity assessed by a wPCDAI \>40 will be eligible for inclusion after a diagnosis of CD was made based on the Porto criteria.~Exclusion Criteria:~Patients with the following characteristics will be excluded: immediate need for surgery, symptomatic stenosis or stricture in the bowel due to scarring, active perianal fistulas, severe co-morbidity, severe infection such as sepsis or opportunistic infections, positive stool culture, positive Clostridium difficile assay, positive tuberculin test or a chest radiograph consistent with tuberculosis or malignancy, those already started with CD specific therapy.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Top-down (Type: EXPERIMENTAL): Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
- Step-up (Type: ACTIVE_COMPARATOR): Prednisolon and azathioprine; Patients will receive induction treatment with oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, then tapering of prednisolone in 6 weeks until stop, and receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* New Néevo®/NéevoDHA® Start.~* Only for women who are pregnant and taking brand name Néevo®/ NéevoDHA® under a physicians care.~Exclusion Criteria:~* Patients who are not pregnant.~* If participant indicates that she did not get a prescription for Néevo®/ NéevoDHA®, she will not be able to complete the survey(s).~* For the follow-up survey, if the participant indicates that she has not been taking Néevo®/NéevoDHA®, she will not be able to complete the survey( (s).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- Néevo®/NéevoDHA® (Type: None): Subjects who have been prescribed Néevo/NéevoDHA® daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bupivacaine, Levobupivacaine and Ropivacaine After Intrathecal and Extradural Injection in Labour

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is aged \> 18 years~* The patient is in early labour ≤ 5cm cervical dilatation~* The patient is American Association of Anaesthesiologists Grade I - II~* The patient provides written informed consent to participate in the trial prior to surgery~Exclusion Criteria:~* The patient has any known chronic medical condition for which regular medication is required~* The patient has received any investigational drug within the 90 days prior to the study or is scheduled to receive one during the study period~* The patient is scheduled for caesarean section~* The patient has received opioids in the last 4 hours~* The patient has evidence of alcohol or drug abuse~* There is evidence of obstetric complications~* The fetus has shown signs of intrauterine growth retardation~* The patient has findings on pre-study evaluations (e.g. laboratory results, medical history, physical examination, ECG) that are clinically significant in the investigator's opinion such to exclude entry into the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Extradural bupivacaine (Type: ACTIVE_COMPARATOR): Local anesthetic
- Extradural levobupivacaine (Type: ACTIVE_COMPARATOR): local anaesthetic
- Extradural ropivacaine (Type: ACTIVE_COMPARATOR): local anaesthetic
- Intrathecal bupivacaine (Type: ACTIVE_COMPARATOR): local anaesthetic
- Intrathecal levobupivacaine (Type: ACTIVE_COMPARATOR): local anaesthetic
- Intrathecal ropivacaine (Type: ACTIVE_COMPARATOR): local anesthetic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of HIV~* Switching antiretroviral regimen(s) for the first time at the start of the study~Exclusion Criteria:~* Currently pregnant~* Presence of active tuberculosis, Hepatitis B, and/or Hepatitis C and receiving treatment for the condition(s) during the study period~* Presence of active pneumonia or other signs of opportunistic infections at the start of the study~* Currently participating in a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raltegravir + 2 NRTIs (Type: None): Raltegravir is an integrase inhibitor. Two Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
- NNRTI + 2 NRTIs (Type: None): Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) could include: delavirdine, efavirenz, etravirine, rilpivirine, nevirapine; and two NRTIs.
- PI + 2 NRTIs (Type: None): Protease inhibitors (PI) could include: nelfinavir, lopinavir, saquinavir, tipranavir, atazanavir and darunavir; and two NRTIs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Montelukast Have an Affect on the Function of the Artery in Patients With Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female age 18-80 years, diagnosis of acute coronary syndrome with one increased Troponin assay,chest pain or chest pain syndrome, stable on initial medical therapy, painfree x 6 hours prior to enrollment~Exclusion Criteria:~* STEMI, Q-wave MI, \< 18years, women of childbearing potential, new LBBB, recurrent chest pain since hospitalization, IV nitroglycerine drip, hemodynamically unstable, history of asthma, history of liver disease or abnormal liver enzymes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast sodium (Type: ACTIVE_COMPARATOR): Drug arm - Montelukast as a single dose 100 mg. To test the hypothesis of leukotriene inhibition.
- 2 (Type: PLACEBO_COMPARATOR): No drug given - no placebo available. To compare with active drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Marine Oils and Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rheumatoid arthritis patients according to American College of Rheumatology criteria (with active disease and in remission). Intensity of joint pain last week (30 mm or more on 100 mm Visual analogue scale). Stable use of DMARDS and no corticosteroid injections last 4 weeks before study and during study.~Exclusion Criteria:~* Non-Norwegian speaking/reading or not understanding study design or non-compliance. Pregnant/lactating women. Bleeder disease, known HIV or hepatitis, medication with Marevan (blood thinner). Not willing or possible to stop taking regular omega-3 supplements during study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Whale blubber oil
- 2 (Type: ACTIVE_COMPARATOR): Cod liver oil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Oral Nutritional Supplements With Specialized Nutrients on Functional Recovery and Morbidity After Gastrointestinal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who are \> 50 years of age and \< 80 years~2. Patients who have signed a written Informed Consent (Appendix I) prior to admission to the study.~3. Patients who have an ECOG performance status (presurgery) of 0, 1 or 2 (Appendix II).~4. Patients able to orally consume 500 mL or more of liquid a day after adaption~5. Patients undergoing elective gastrointestinal surgery \[e.g. Colorectal surgery: colectomy, hemicolectomy, proctectomy; Small bowel resection/surgery; liver resection, splenectomy, non-whipple pancreatic surgery\]~Exclusion Criteria:~1. Patients who are \> 80 years of age and \< 50 years~2. Patients who have co-morbid conditions, uncontrolled metabolic conditions or psychiatric conditions that might make tolerance or evaluation of the feeding formula difficult;~3. Patients undergoing Whipple´s procedure, gastrectomy, oesophageal resection~4. Patients who get preoperative nutritional support~5. Patients taking supplements (EPA, DHA)~6. Any concomitant severe disease e.g.~   * Patients with respiratory failure (FEV\<0.8l/sec)~  * Patients with renal failure (Cr \> 3mg/dl or dialysis patients)~  * Patients with hepatic dysfunction (Child \>A)~  * Patients with cardiac failure (NYHA \> III)~7. Patients suffering from an intestinal obstruction or ileus~8. Patients with an Hb level of \>8 g/dL experiencing gastrointestinal haemorrhaging~9. Patients with HIV~10. Patients requiring immunosuppression treatments~11. Pregnancy~12. Patients undergoing emergency surgery~13. Other patients determined by a study investigator to be inappropriate for enrolment in this study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Resource Support® Novartis
- 2 (Type: ACTIVE_COMPARATOR): Resource Protein®, Novartis
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject provides informed consent~* Subject is \>18 years of age~* Subject is deemed competent for making medical decisions~* Subject is scheduled to undergo chemotherapy followed by surgery and then IMRT~* Subject is a surgical candidate~* A negative pregnancy test is required in women of child-bearing potential, as standard of care.~Exclusion Criteria:~•Subject is \<18 years old.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility